Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 120,537

Document Document Title
WO/2017/037812A1
The purpose of the present invention is to provide a patch preparation which uses a basic drug acid addition salt as a raw material and which has excellent skin permeability of the drug. This patch preparation is formed by providing an a...  
WO/2017/036397A1
Provided is a spray of ganoderma lucidum spore extract having undergone supercritical CO2 extraction.  
WO/2017/038925A1
The present invention addresses the problem of providing a pharmaceutical composition that has a high safety and with which the long-term stability can be ensured and the reduction in the amount of an active ingredient accompanying the o...  
WO/2017/037089A1
Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples ...  
WO/2017/039525A1
The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time pe...  
WO/2017/035733A1
Provided are a conjugate of memantine and arctigenin, and a pharmaceutical composition comprising the conjugate. The conjugate can treat diseases associated with Aβ or Tau protein pathways, such as Alzheimer's disease or Parkinson's dis...  
WO/2017/040603A1
Described herein are dosing regimens and kits comprising (3R, 4R, 5S)-5-(difluoromethyl)piperidine-3.4-diol for the treatment and/or prevention of lysosomal storage disorders such as Gaucher disease. Also described are dosing regimens an...  
WO/2017/040611A1
An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L- theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).  
WO/2017/036436A1
The present invention provides primin derivatives of general formula II and/or III, wherein R1 is selected from the group consisting of methyl and hydrogen, R2 is selected from the group consisting of methoxy, hydroxy, hydrogen, R3 is se...  
WO/2017/040545A1
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or method...  
WO/2017/037091A1
Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to stabilize or improve mood, modulate excessive emotional distress, reduce anxiety, and/or reduce stress. In an embodiment, the composition can be administered d...  
WO/2017/036118A1
An injectable Aripiprazole suspension preparation, comprising cellulose-based suspending agents and polyoxyethylene (20) Sorbitan Monooleate. Said suspension preparation has good stability, having an extended shelf life.  
WO/2017/036978A1
The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  
WO/2017/037105A1
B. longum ATCC BAA-999, or a composition comprising B. longum ATCC BAA-999, for use in an individual to; support breastfeeding initiation and/or to optimise breastfeeding duration and/or to optimize the quality and/or quantity ofbreast m...  
WO/2017/040449A1
The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxi...  
WO/2017/040451A1
The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxi...  
WO/2017/037079A1
The invention relates to a 5H-dibenz[b,f]azepine-5-carboxamide derivative such as carbamazepine (CBZ) for use in a method for preventing or treating Andermann syndrome.  
WO/2017/038861A1
Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is a...  
WO/2017/040879A1
The invention provides heterobicyclic pyrimidinone compounds such as thiazolo[3,2-a]pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical diso...  
WO/2017/035631A1
The invention provides improved supplemental compositions, and methods for administering same to a user, for enhancing the onset, quality, and duration of sleep in humans and animals. The supplemental composition may contain a combinatio...  
WO/2017/038945A1
Provided is a therapeutic agent for diseases associated with the accumulation of abnormal substances in cells which contains, as an active ingredient, a substance for suppressing the expression of ERdj8, or a substance for suppressing an...  
WO/2017/036392A1
A derivative of inula lineariifolia lactone A, and in particular, a dimethylamine 4-O-acetyl inula lineariifolia lactone A or a salt thereof, preparation for same, and an application of same in preparation of medicine for treating multip...  
WO/2017/035801A1
A hericium erinaceus active substance, a preparation method for the active substance, and a pharmaceutical composition including the active substance. The active substance is prepared via the following steps: (a) placing a hericium erina...  
WO/2017/041054A1
Disclosed here are compositions and methods for preventing or treating certain health conditions associated with inflammation or oxidative stress. These compositions are prepared from ingredients containing phytochemicals that activate t...  
WO/2017/037661A1
The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions com...  
WO/2017/038656A1
The present invention provides: a novel tetrahydroazepine compound; and a method for producing the tetrahydroazepine compound. The present invention relates to: a tetrahydroazepine compound represented by general formula (10) (wherein R1...  
WO/2017/037813A1
The purpose of the present invention is to provide a transdermal absorption composition which has improved skin permeability of a basic drug, and a transdermal absorption promoter of a basic drug. This purpose is met by a transdermal abs...  
WO/2017/040877A1
The invention provides heterobicyclic pyrimidinone compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's dise...  
WO/2017/036318A1
Provided are a 1,2,3,4-tetrahydroisoquinoline derivative having the structure of formula (I), a preparation method therefor and an application thereof. The compound of formula (I) may be used for the development of drugs for primary neur...  
WO/2017/038767A1
The purpose of the present invention is to provide: a transdermally absorptive composition having improved basic drug skin penetration properties; and a transdermal absorption accelerator for a basic drug. The purpose can be achieved by ...  
WO/2017/038768A1
The purpose of the present invention is to provide a patch preparation which uses a basic drug acid addition salt as a raw material and which has excellent skin permeability of the drug. This patch preparation is formed by providing an a...  
WO/2017/037670A1
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods ...  
WO/2017/040301A1
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g.,...  
WO/2017/037081A1
The present invention relates to new compounds of formula (1) wherein R is -C(=O)CH2OH or -CH(OH)CH2OH; R1, is =O or OH; R2 is H or OH; R3 is H or C1-C4alkyl; R4 is H or C1C4alkyl. These compounds are obtained by a process using at least...  
WO/2017/034420A1
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...  
WO/2017/035224A1
Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are ...  
WO/2017/034872A1
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of d...  
WO/2017/033963A1
The present invention addresses the problem of providing a substance that has an effect of increasing ATP in cells, in particular, an ATP increasing agent that has an effect much stronger than the increasing effect achieved by using inos...  
WO/2017/034418A1
The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.  
WO/2017/032874A1
The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon ora...  
WO/2017/034027A1
The present invention provides an adhesive patch that is capable of exhibiting excellent tackiness when adhered to the skin and reduces peeling from the skin once adhered thereto. This adhesive patch is characterized by including: a supp...  
WO/2017/033966A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1, R2a, R2b, R3, R4, R5, R9a, R9b, R10, R11, X, Y and Z are as defined in the description.)  
WO/2017/033093A1
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of tre...  
WO/2017/033019A1
There is provided compounds of formula I, (I) wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the...  
WO/2017/033946A1
The present invention provides a heterocyclic compound which has an HDAC inhibitory effect and is useful for treating inflammatory diseases and the like, and a medicine containing the heterocyclic compound. The present invention pertains...  
WO/2017/035472A1
Provided are pharmaceutical formulations that include an amyloid polypeptide including at least one D-amino acid, and a pharmaceutically acceptable carrier. Also provided are kits that include the pharmaceutical formulations. Methods tha...  
WO/2017/033951A1
Provided is a novel analgesic. This analgesic is obtained by including an interleukin-31 agonist as an active ingredient.  
WO/2017/030968A1
One of the aspects of the invention is directed toward a method of treating or preventing acute brain or nerve injury in a subject, comprising administering an effective amount of posiphen, or a pharmaceutically acceptable salt of posiph...  
WO/2017/030171A1
[Problem] To provide a compound which has a positive allosteric modulating effect (PAM effect) for an α7 nicotinic acetylcholine receptor (α7 nACh receptor). [Solution] The inventors have achieved the present invention by making studie...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  

Matches 51 - 100 out of 120,537